BioAxone Therapeutics

BioAxone Therapeutics is a clinical-stage biotechnology company developing regenerative therapies for neurological and neurovascular disorders. The company specializes in the Rho signaling pathway, which regulates axon regrowth and vascular integrity after injury. Their lead program, VX-210 (Cethrin), is a Rho inhibitor licensed to Vertex Pharmaceuticals for acute spinal cord injury. BioAxone is also developing BA-1049, a selective ROCK2 inhibitor for cerebral cavernous malformation, and other candidates for ophthalmic conditions. The company's approach leverages deep expertise in Rho-kinase biology to address unmet needs in neurotrauma and rare vascular diseases. BioAxone is headquartered in Cambridge, Massachusetts, and continues to advance its pipeline through both internal development and strategic partnerships.